Meeting Coverage

The ACR’s first-rate education program showcases cutting-edge and timely topics in rheumatology, as well as the prevention, diagnosis, and treatment of rheumatic diseases and related comorbid conditions. ACR Convergence...

Using 2017 USRDS data, researchers identified dialysis patients aged 18 and older with Medicare as the primary payer. Baseline characteristics and comorbid conditions for patients with gout who were dialysis-dependent were...

Prior research has shown that pegloticase therapy for uncontrolled gout does not require renal adjustments and is effective across all stages of CKD. Pegloticase with immunomodulating (IMM) co-therapy demonstrated an increased...

Since patients with CKD are at increased risk for gout and alkalinization solubilizes uric acid, investigators sought to determine if baseline bicarbonate or change in bicarbonate was an independent predictor of incident gout in...

With evidence that gout highly impacts patients with advanced CKD, through increased healthcare utilization and higher cardiovascular and bone/joint comorbidity and patients with uncontrolled gout (UCG) show to have an even...

In patients with chronic refractory gout whose serum urate (SU) was not maintained at ≤6 mg/dL, adding an additional tolerizing dose of pegloticase between the first and second biweekly administrations showed an overall response...

Serum urate (SU) responders to pegloticase experienced significant reductions in mean arterial pressure (MAP) that were independent of changes in renal function, according to prior randomized clinical trials (RCTs). To determine...

Small clinical trials have shown that concomitant immunomodulatory (IMM) drug use improves pegloticase persistence in the treatment of gout. However, real-world evidence has been lacking. Therefore, researchers evaluated...

In a large cohort of older patients with gout who started urate-lowering therapy (ULT), researchers observed a decrease in the rate in major adverse cardiovascular events (MACE) with a treat-to-target (TTT) strategy compared...

Magnetic resonance imaging (MRI) and clinical characteristics could differentiate between aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), relapsing-remitting multiple sclerosis (RR-MS), and...

Most patients with neurovascular age-related macular degeneration (nAMD) would not qualify for the trials that inform currents standards of care, according to a study presented at the 39th Annual Scientific Meeting of ASRS 2021...

Only one-third of Medicare beneficiaries with neovascular age-related macular degeneration (nAMB) were “persistent” with anti-VEGF monotherapy treatment each year, according to a study presented at the 39th Annual Scientific...

Geographic disparities in access to clinical trial sites exist for neovascular age-related macular degeneration (nAMD) in the United States, according to a study presented at the 38th Annual Scientific Meeting of the American...

Investigators sought to assess the impact of telerehabilitation in patients with MS during the isolation period of the COVID-19 pandemic. They conducted a retrospective analysis using medical records from adults with MS and...

Data presented at prior CMSC meetings described baseline, 1-year, and 2-year results of the Multiple Sclerosis Achievement Center, which assessed day wellness programs targeting physical, cognitive, and social well-being in...